Nureca (Small Cap) Share Target 2024, 2025 To 2039
|
Nureca Limited |
|||
|
Price: ₹278.40 | ||
| 52 Week Low: ₹240.00 52 Week High: ₹468.80 |
|||
| Market Capital: 271.3 Crore (Smallcap) | |||
| Healthcare -> Medical Devices | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Nureca Share Price Target For 2024
- 1.1.1: Nureca Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Nureca Share Price Target For 2025
- 1.2.1: Nureca Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Nureca Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Nureca Brief Company Overview
- 4: Nureca Financial Performance
- 4.0.1: Is Nureca A Good Buy For Long Term?
To predict the Nureca's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Nureca Share Price Target For 2024
The line chart displays the monthly closing prices of Nureca with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Nureca shares in 2024, see the table below.
Nureca Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 289.0 (+3.8%) | Price Action: 11 Dec 2024 High |
| 2024 Target 2 | 286.0 (+2.72%) | Price Action: 18 Dec 2024 Low |
| 2024 Target 1 | 282.75 (+1.56%) | Price Action: 16 Dec 2024 Low |
| Current Price | 278.40 | Nureca's share price as of 23 Dec 2024 |
| Stop Loss 1 | 276.4 (-0.72%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 2 | 271.95 (-2.31%) | Price Action: 22 Nov 2024 Low |
| Stop Loss 3 | 268.85 (-3.44%) | Price Action: Oct 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Nureca is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹283.86 serves as the nearest technical reference point.
Historical Returns: 3-month: -22.45% | 6-month: +5.01% | 1-year: -34%
Nureca Share Price Target For 2025
The line chart displays the monthly closing prices of Nureca with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Nureca shares in 2025, see the table below.
Nureca Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 439.34 (+57.8%) | Price Action: Chart |
| 2025 Target 2 | 431.15 (+54.86%) | Price Action: Chart |
| 2025 Target 1 | 426.88 (+53.33%) | Fibonacci Extension Level 64.90% |
| Current Price | 278.40 | Nureca's share price as of 23 Dec 2024 |
| Stop Loss 1 | 243.2 (-12.65%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 2 | 240.0 (-13.8%) | Price Action: Jun 2024 Low |
| Stop Loss 3 | 235.68 (-15.35%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Nureca is currently trading near its 52-week low of ₹240, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -34% | 3-year: -85.89% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Nureca Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹278.40 | ||
| 2024 | ₹273.19 | -1.87% | ₹277.29 |
| 2025 | ₹179.83 | -34.17% | ₹265.40 |
| 2026 | ₹225.10 | +25.17% | ₹251.05 |
| 2027 | ₹190.92 | -15.18% | ₹228.72 |
| 2028 | ₹206.09 | +7.94% | ₹214.04 |
| 2029 | ₹187.51 | -9.01% | ₹203.13 |
| 2030 | ₹261.87 | +39.65% | ₹265.80 |
| 2031 | ₹256.73 | -1.96% | ₹260.58 |
| 2032 | ₹247.62 | -3.54% | ₹257.09 |
| 2033 | ₹242.53 | -2.05% | ₹249.83 |
| 2034 | ₹238.49 | -1.66% | ₹242.58 |
| 2035 | ₹233.08 | -2.26% | ₹237.76 |
| 2036 | ₹227.86 | -2.23% | ₹231.83 |
| 2037 | ₹219.13 | -3.83% | ₹228.07 |
| 2038 | ₹213.98 | -2.35% | ₹220.82 |
| 2039 | ₹210.04 | -1.84% | ₹213.56 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Nureca Brief Company Overview
Nureca Limited: Enhancing Healthcare and Wellness Established in 2016, Nureca Limited, a leading provider of healthcare and wellness products in India, has garnered a strong reputation for its commitment to delivering innovative solutions that address various health...
concerns. Diverse Product Range: Nureca offers an extensive range of products, including chronic disease management devices, orthopedic products, home healthcare essentials, mother and baby care items, nutritional supplements, and fitness tracking devices, catering to diverse healthcare needs. Market Presence: The company's products are marketed through e-commerce platforms, distributors, and retailers, ensuring a wide reach and accessibility across the nation. Commitment to Innovation: Nureca is dedicated to constantly developing and introducing new products that leverage the latest technologies to improve health outcomes and enhance overall well-being. Chronic disease management products Orthopedic products Humidifiers and steamers Mother and baby care products Nutritional supplements ECG productsNureca Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 271.3 Crore | Market valuation of Nureca's shares. |
| Revenue (TTM) | 90.8 Crore | Total revenue generated by Nureca over the past twelve months. |
| Net Income (TTM) | -2.8 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -9.55% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -3.09% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-0.5% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
2.73 | Company's total debt divided by total shareholder equity. |
| Total Debt | 5.3 Crore | Sum of Nureca's current & long-term financial obligations. |
| Total Cash | 28.28 Crore | Total amount of liquid funds available to Nureca. |
| Beta | 0.41 | Beta is less than 1 indicating that the Nureca's price is less volatile than the market. |
Is Nureca A Good Buy For Long Term?
Nureca, a small-cap stock with a market capitalization of ₹271.3 crore, presents a mixed picture for long-term investors. While it boasts ₹28.28 crore in cash and a relatively low debt of ₹5.3 crore (Q2 2024-25), its recent performance is concerning. A negative net profit of ₹2.8 crore (TTM) and a -3.09% profit margin, coupled with significant negative returns over the past year (-36.60% YTD), indicate considerable financial challenges. Therefore, based on the provided data, Nureca is not a good buy for the long term. Further investigation into the reasons for declining revenue and profitability is crucial before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
